Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated filings document the formal disclosures of a large health care company organized around UnitedHealthcare and Optum. Proxy materials describe board governance, executive compensation, shareholder voting matters and the company’s complementary businesses: UnitedHealthcare health coverage and Optum clinical, data, product, pharmacy and care services.
Current reports on Form 8-K cover operating and financial results, Regulation FD communications, strategy and market-position discussions, director appointments, compensation arrangements and other material-event disclosures. The filing record also documents governance practices, capital-structure and compensation matters, risk-related business context and the regulatory reporting framework for a Delaware public operating company in the health care sector.
UnitedHealth Group Incorporated plans to participate in the Bank of America Securities Health Care Conference 2026. Senior leaders will answer questions in an interview-style session covering the company’s strategy, market positions, recent results and expectations for its end markets.
The session is scheduled for May 12, 2026, beginning at 11:00 a.m. Eastern Time, and a live audio webcast will be accessible through the Investor Relations page on the company’s website. The disclosure is furnished under Regulation FD and is not deemed filed or incorporated by reference into other securities law filings unless specifically referenced.
UnitedHealth Group reported Q1 2026 results with modest growth and stable profitability. Total revenues were $111,721 million, up 2% year over year, while net earnings were $6,481 million and diluted EPS was $6.90, roughly in line with 2025.
UnitedHealthcare revenues rose 2% to $86,265 million, but medical membership fell by 1.1 million people, mainly in Medicare Advantage, Medicaid and commercial risk-based products. Optum revenues were flat at $63,749 million and earnings from operations declined 15% as value-based care businesses faced elevated medical cost trends and Medicare funding pressure.
The medical care ratio improved to 83.9% from 84.8% on favorable reserve development and affordability initiatives, while the operating cost ratio increased to 13.8% due to investments and restructuring. Cash flows from operations were strong at $8,912 million. The company executed portfolio divestitures, is exiting South American operations, plans about $3.0 billion of pending acquisitions, entered forward share repurchase contracts up to $2.0 billion, and received IRS Notices of Proposed Adjustment for 2017–2020 transfer pricing, which it intends to contest.
UnitedHealth Group Inc reports that Vanguard Capital Management beneficially owned 68,122,483 shares of Common Stock as of 03/31/2026, representing 7.50% of the class. The filing states Vanguard has sole dispositive power over 68,122,483 shares and sole voting power over 9,251,706 shares. The disclosure notes ownership is held on behalf of various Vanguard affiliates and managed accounts.
UnitedHealth Group executive Patrick Hugh Conway, Chief Executive Officer of Optum, reported an open-market sale of 800 shares of UnitedHealth Group common stock. The shares were sold at a price of $355.00 per share. After this transaction, he directly holds 17,804.991 shares of common stock.
Fidelity Brokerage Services LLC submitted a Form 144 notice to sell up to 800 shares of Common Stock of UNH. The filing lists two tranches that vested: 301 shares on 02/20/2026 and 499 shares on 02/21/2026. The cover shows an aggregate amount of $284,000.00 and CUSIP 907675839 with the securities traded on NYSE.
UnitedHealth Group outlines its 2026 annual meeting agenda and broad governance, leadership and pay changes. Shareholders will vote on electing nine directors, an advisory Say‑on‑Pay, ratifying Deloitte & Touche as auditor, and a shareholder proposal on requiring an independent Board chair.
The company reports 2025 revenue of $447.6 billion, net earnings of $12.1 billion, fully diluted EPS of $13.23, ROE of 12.8% and an annual cash dividend of $8.84 per share. It plans to invest nearly $1.5 billion in AI initiatives in 2026 and at least that much again in 2027.
Governance updates include combining the CEO and Chair roles under Stephen Hemsley with a strengthened Lead Independent Director, creating a new Public Responsibility Committee, refreshing committee leadership and adding former FDA Commissioner Scott Gottlieb to the Board. Pay decisions include a $60 million cliff‑vesting stock option grant to the CEO, no annual bonus, and increasing CEO stock ownership requirements, while the CFO receives a $1 million salary, targeted 2x‑salary bonus, and $8 million in stock incentives plus a $1.2 million cash award.
UnitedHealth Group reported first quarter 2026 revenues of $111.7 billion, up 2% year-over-year, with earnings from operations of $9.0 billion and net margin of 5.6%. Diluted earnings were $6.90 per share and adjusted earnings were $7.23 per share, both slightly above the prior year.
The medical cost ratio improved to 83.9%, down 90 basis points, while the operating cost ratio rose to 13.8% as the company invested in people, technology and modernization. Cash flows from operations were $8.9 billion, or 1.4 times net income, and the debt-to-capital ratio was 42.9% as of March 31, 2026.
Management raised its full year 2026 earnings outlook to greater than $17.35 per share and adjusted earnings to greater than $18.25 per share. During the quarter, UnitedHealth agreed to acquire Alegeus Technologies, completed the sale of the Optum UK business with $400 million in net proceeds committed to the United Health Foundation, and put in place an arrangement to repurchase at least $2.0 billion of common stock by the end of the second quarter 2026.
HOOPER MICHELE J reported acquisition or exercise transactions in this Form 4 filing.
UnitedHealth Group director Michele J. Hooper received a grant of 206 deferred stock units of common stock on April 1, 2026 as regular quarterly compensation for Board service. The units are immediately vested but must be held until her Board service ends, bringing her direct holdings to 41,792 shares/units. This is a routine compensation-related equity award rather than an open-market purchase or sale.
MCNABB FREDERICK WILLIAM III reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director Frederick William McNabb III received a grant of 388 deferred stock units of common stock as regular quarterly compensation for Board service. These units are immediately vested but must be held until he completes his service on the Board, and his direct holdings after the award total 15,162 shares.
Baker Charles D. reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director Charles D. Baker received 343 deferred stock units of Common Stock as part of his regular quarterly board compensation. The units are immediately vested but must be held until he completes his service on the Board, bringing his direct holdings to 2,163 shares.